Showing results (651-660 of 670) with videos related to

Sort By:
Pageof 67
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 25, 2012
Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW)G Ioannidis, J Flahive, L Pickard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
JCO Precision Oncology|November 14, 2025
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule InhibitorFrank W J Heijboer, Marta Brambilla, Mario Occhipinti, et al.
Ebiomedicine|October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinomaLoic Verlingue, Antoine Italiano, Hans Prenen, et al.
The Journal of Clinical Endocrinology and Metabolism|October 27, 2020
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX MutationsOlivera Casar-Borota, Henning Bünsow Boldt, Britt Edén Engström, et al.
ESMO Open|September 21, 2018
Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine ProgrammeColin R Lindsay, Emily C Shaw, Fiona Blackhall, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Nature Communications|November 24, 2011
P-Rex1 is required for efficient melanoblast migration and melanoma metastasisColin R Lindsay, Samuel Lawn, Andrew D Campbell, et al.
Acta Neuropathologica|November 23, 2024
Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumorsJelena Jotanovic, Henning Bünsow Boldt, Mark Burton, et al.
Pageof 67